Low CETP Activity
0
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Merck & Co.RAHWAY, NJ
1 programRelationship Between CETP Deficiency and Atherosclerosis in Patients With HyperalphalipoproteinemiaN/A
MSDIreland - Ballydine
1 programRelationship Between CETP Deficiency and Atherosclerosis in Patients With HyperalphalipoproteinemiaN/A1 trial
Active Trials
Sharp TherapeuticsPA - Pittsburgh
1 programRelationship Between CETP Deficiency and Atherosclerosis in Patients With HyperalphalipoproteinemiaN/A
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MSDRelationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
Clinical Trials (1)
Total enrollment: 1,500 patients across 1 trials
NCT01916512MSDRelationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
Start: Feb 20121,500 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.